PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$98.52
-2.66% today
Updated 2026-04-29
Market cap
$6.34B
P/E ratio
—
P/S ratio
137.68x
EPS (TTM)
$-2.05
Dividend yield
—
52W range
$41 – $108
Volume
0.8M
Protagonist Therapeutics Inc (PTGX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-74.0%
Last 4 quarters
Revenue YoY growth
-95.6%
Most recent quarter
EPS YoY growth
-134.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.4%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-5.5%
2025-08-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-18 | $-0.69 | -102.8% | $97.23 | $101.68 | +4.6% |
| 2025-11-06 | $-0.62 | +1.6% | $77.88 | $79.54 | +2.1% |
| 2025-08-06 | $-0.55 | +5.2% | $53.90 | $50.96 | -5.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.34 | $-0.69 | -102.8% | $7.44M | -95.6% |
| 2025-09-30 | $-0.63 | $-0.62 | +1.6% | $4.71M | +0.8% |
| 2025-06-30 | $-0.58 | $-0.55 | +5.2% | $5.55M | +33.1% |
| 2025-03-31 | $0.11 | $-0.19 | -272.7% | $28.32M | -88.9% |
| 2024-12-31 | $0.25 | $1.98 | +692.0% | $170.64M | +184.4% |
| 2024-09-30 | $-0.60 | $-0.54 | +10.0% | $4.67M | — |
| 2024-06-30 | $-0.60 | $-0.50 | +16.7% | $4.17M | — |
| 2024-03-31 | $1.19 | $3.26 | +173.9% | $254.95M | — |
| 2023-12-31 | $-0.03 | $0.44 | +1566.7% | $60.00M | — |
| 2023-09-30 | $-0.69 | $-0.58 | +15.9% | — | — |
| 2023-06-30 | $-0.65 | $-0.68 | -4.6% | — | — |
Frequently asked questions
Has Protagonist Therapeutics Inc beaten earnings estimates?
Protagonist Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -74.0% over the last 4 quarters.
How does PTGX stock react to earnings?
PTGX stock has moved an average of +0.4% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Protagonist Therapeutics Inc's revenue growth rate?
Protagonist Therapeutics Inc reported year-over-year revenue growth of -95.6% in its most recent quarter, with EPS growing -134.8% year-over-year.